Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

70.35
-1.6300-2.26%
Pre-market: 68.48-1.8700-2.66%07:29 EDT
Volume:9.01M
Turnover:639.73M
Market Cap:12.77B
PE:-49.07
High:73.09
Open:70.10
Low:68.66
Close:71.98
52wk High:104.32
52wk Low:40.77
Shares:181.56M
Float Shares:115.00M
Volume Ratio:1.09
T/O Rate:7.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:28.71
PE(LYR):-49.89

Loading ...

Tempus AI Wins FDA Clearance for ECG-MR Tool to Flag Undiagnosed Mitral Regurgitation

Reuters
·
Sep 28

Tempus Receives FDA Clearance for Its Ecg-Mr AI Product Designed to Identify Undiagnosed Mitral Regurgitation

THOMSON REUTERS
·
Sep 28

A $10–12 Trillion Bubble With All Four Fuses Lit? The Chanos–Marcus Case Against AI

Analyst Calls
·
Sep 28

Tempus AI's Officer Eric Lefkofsky sold 726,406 shares

Filings Track
·
Sep 25

Tempus AI CEO and Chairman Eric P. Lefkofsky Disposes of $17,868,777.62 in Class a Shares

Reuters
·
Sep 25

Tempus AI Inc Stock (TEM) Closed Up by 7.38% on Sep 24: What Investors Need To Know

TradingKey
·
Sep 25

tempus AI Inc Class A call volume above normal and directionally bullish

TIPRANKS
·
Sep 25

Movement Alert|Tempus AI Rises 5.07% in Regular Trading, Boosted by Extended Recursion Data License and RNA Model Authorization

Market Focus
·
Sep 24

Morgan Stanley: Semiconductors To Reach $1.5T In 2030, AI Semis ~50% Of The Pie

Analyst Calls
·
Sep 24

Form 144 | Tempus AI's Officer and Director Eric Lefkofsky proposes to sell 250,000 Shares, with a total value of approximately $19.51 Million.

Filings Track
·
Sep 23

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Avantor (AVTR)

TIPRANKS
·
Sep 22

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21

Recursion, Tempus Expand AI and RNA Collaboration Agreements

TIPRANKS
·
Sep 21

Tempus AI, Recursion extend data license agreement, enter new license agreement

TIPRANKS
·
Sep 21

Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm

THOMSON REUTERS
·
Sep 21

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model

THOMSON REUTERS
·
Sep 21

Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029

THOMSON REUTERS
·
Sep 21

Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target

MT Newswires Live
·
Sep 21